DHM, a plant-derived flavonoid, consistently reduced alcohol-induced liver damage and oxidative stress in animal and cell studies , but only two small human trials exist, neither testing isolated DHM directly. Well-designed clinical trials are needed before therapeutic recommendations can be made.
Researchers conducted a systematic review of 22 studies examining dihydromyricetin (DHM), a naturally occurring compound found in plants like the Hovenia dulcis tree, for its effects on alcohol-related conditions. The analysis included laboratory experiments (8 in vitro, 17 in vivo) and 2 human trials. The findings paint a picture of robust preclinical activity shadowed by minimal clinical evidence.
Across experimental models, DHM consistently demonstrated several protective effects against alcohol-induced damage. The compound reduced markers of liver injury (AST and ALT enzymes), lowered oxidative stress through enhanced antioxidant defenses, and suppressed inflammatory responses. It also preserved mitochondrial function, protected the intestinal barrier, and prevented hepatic steatosis (fatty liver accumulation). These effects appeared to operate through well-characterized molecular pathways including Nrf2 and AMPK signaling, which regulate cellular stress responses and energy metabolism respectively.
However, the clinical translation gap is substantial. The only human evidence came from two small trials using Hovenia dulcis extracts (which contain DHM but are not isolated DHM), and these showed reductions in hangover severity and some inflammatory markers. Neither trial directly evaluated isolated DHM as a therapeutic agent for alcohol-related disorders like alcohol use disorder or alcohol-associated liver disease. The review also noted inconsistent findings regarding ethanol metabolism and neurobehavioral outcomes across preclinical studies, suggesting DHM's effects may be tissue-specific or dependent on dosing and experimental conditions.
The authors explicitly acknowledged critical limitations: preclinical studies varied widely in design, no formal risk-of-bias assessment was conducted (due to heterogeneity), and the leap from cell culture to human patients remains unvalidated. This is standard territory for early-stage supplement research, where mechanistic plausibility often outpaces clinical proof.
DHM represents a research signal worth monitoring, not a current recommendation. The preclinical evidence is encouraging for liver protection specifically, but several caveats apply:
For alcohol consumption and liver health: If you consume alcohol regularly, current evidence supports well-established protective strategies: alcohol reduction, maintaining adequate sleep, antioxidant-rich foods, and regular exercise. DHM has not been tested in humans with alcohol use disorder or alcohol-associated liver disease.
On supplement use: DHM is available commercially, often in Hovenia dulcis extracts marketed for "hangover support." The hangover trials showed modest benefit, but hangover severity is not the same as preventing alcohol-related organ damage. There are no safety data from extended human use, and no trials establishing optimal dosing.
Next steps in research: This review makes clear that the field needs randomized controlled trials in humans using standardized, isolated DHM formulations. Until those exist, therapeutic claims would exceed the evidence.
If you have alcohol use concerns or liver disease, work with a healthcare provider on evidence-based approaches rather than relying on experimental compounds.
| Parameter | Details |
|---|---|
| Study type | Systematic review (narrative synthesis, no meta-analysis) |
| Studies included | 22 total: 8 in vitro, 17 in vivo animal/tissue models, 2 human trials |
| Human participants | Small sample across 2 trials; neither used isolated DHM |
| Compound | Dihydromyricetin (DHM), a plant-derived flavonoid |
| Primary outcomes | Liver injury markers, oxidative stress, inflammation, hepatic steatosis, mitochondrial function |
| Evidence quality | Preclinical: consistent but heterogeneous; Clinical: minimal and indirect |
| Journal | Nutrients |
| Registration | Unregistered; no prior protocol |
| Key limitation | Large gap between preclinical efficacy and absence of human efficacy/safety trials |
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.